Paper36057729
Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles.
Leal AF and 9 others. Sci Rep, 2022. Cited by 26 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles. Papers, record 36057729. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36057729
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Chondroitinsulfatases | Major topic |
| Mucopolysaccharidoses | Major topic |
| Mucopolysaccharidosis IV | Major topic |
| Nanoparticles | Major topic |
| Clustered Regularly Interspaced Short Palindromic Repeats | |
| Ferrosoferric Oxide | |
| Gene Editing | |
| Glycosaminoglycans | |
| Humans |
Source PubMed
References74
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33636292 | Evaluation of HIV-1 derived lentiviral vectors as transductors of Mucopolysaccharidosis type IV a fibroblasts. | Gene | 2021 | https://conductscience.org/library/papers/33636292 | PubMed |
| 2 | 32529345 | Lysosomal storage diseases: current therapies and future alternatives. | J Mol Med (Berl) | 2020 | https://conductscience.org/library/papers/32529345 | PubMed |
| 3 | 29122734 | Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers. | Eur J Pharm Biopharm | 2018 | https://conductscience.org/library/papers/29122734 | PubMed |
| 4 | 33379360 | Characterization of New Proteomic Biomarker Candidates in Mucopolysaccharidosis Type IVA. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33379360 | PubMed |
| 5 | 28375731 | CRISPR-Cas9 Structures and Mechanisms. | Annu Rev Biophys | 2017 | https://conductscience.org/library/papers/28375731 | PubMed |
| 6 | 26515130 | CCN1/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis. | Cell Signal | 2016 | https://conductscience.org/library/papers/26515130 | PubMed |
| 7 | 22940367 | The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A. | J Mol Biol | 2012 | https://conductscience.org/library/papers/22940367 | PubMed |
| 8 | 33111489 | Human recombinant lysosomal β-Hexosaminidases produced in Pichia pastoris efficiently reduced lipid accumulation in Tay-Sachs fibroblasts. | Am J Med Genet C Semin Med Genet | 2020 | https://conductscience.org/library/papers/33111489 | PubMed |
| 9 | 35581402 | Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA. | Gene Ther | 2023 | https://conductscience.org/library/papers/35581402 | PubMed |
| 10 | 33578874 | Epidemiology of Mucopolysaccharidoses Update. | Diagnostics (Basel) | 2021 | https://conductscience.org/library/papers/33578874 | PubMed |
| 11 | 30560399 | Improved Delivery of CRISPR/Cas9 System Using Magnetic Nanoparticles into Porcine Fibroblast. | Mol Biotechnol | 2019 | https://conductscience.org/library/papers/30560399 | PubMed |
| 12 | 24726177 | Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations. | Mol Genet Metab | 2014 | https://conductscience.org/library/papers/24726177 | PubMed |
| 13 | 32560390 | PH-Responsive, Cell-Penetrating, Core/Shell Magnetite/Silver Nanoparticles for the Delivery of Plasmids: Preparation, Characterization, and Preliminary In Vitro Evaluation. | Pharmaceutics | 2020 | https://conductscience.org/library/papers/32560390 | PubMed |
| 14 | 30323349 | Tailoring the AAV2 capsid vector for bone-targeting. | Pediatr Res | 2018 | https://conductscience.org/library/papers/30323349 | PubMed |
| 15 | 33277608 | Engineering precision nanoparticles for drug delivery. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33277608 | PubMed |
| 16 | 30081189 | CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts. | Gene | 2018 | https://conductscience.org/library/papers/30081189 | PubMed |
| 17 | 31641141 | Evaluation of novel cationic gene based liposomes with cyclodextrin prepared by thin film hydration and microfluidic systems. | Sci Rep | 2019 | https://conductscience.org/library/papers/31641141 | PubMed |
| 18 | 16843502 | Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations. | Mutat Res | 2006 | https://conductscience.org/library/papers/16843502 | PubMed |
| 19 | 34504088 | Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy. | Nat Commun | 2021 | https://conductscience.org/library/papers/34504088 | PubMed |
| 20 | 23227124 | Ultrasound-mediated gene delivery with cationic versus neutral microbubbles: effect of DNA and microbubble dose on in vivo transfection efficiency. | Theranostics | 2012 | https://conductscience.org/library/papers/23227124 | PubMed |
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42782417 | Characterization of Cellular Alterations in a Novel NAGLU Enzyme-Deficient Cellular Model Generated from U-87MG Cell Line. | Neurochem Res | 2026 | https://conductscience.org/library/papers/42782417 | PubMed |
| 42511849 | Modeling Tay-Sachs Disease in Astrocyte-like Cells Reveals Significant Changes in the Transcriptomic Profile. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42511849 | PubMed |
| 42510912 | Advances in Therapies for Mucopolysaccharidoses. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42510912 | PubMed |
| 42449999 | A Comprehensive Update on Pompe Disease: From Existing Therapies to Emerging Curative Strategies. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42449999 | PubMed |
| 41296404 | Long-Term Liver-Targeted AAV8 Gene Therapy for Mucopolysaccharidosis IVA. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/41296404 | PubMed |
| 41088244 | Recent advances in mucopolysaccharidosis IVA treatment. | Orphanet J Rare Dis | 2025 | https://conductscience.org/library/papers/41088244 | PubMed |
| 41034280 | Three-dimensional human mucopolysaccharidosis IVA chondrocyte culture reveals significant impairments in the lysosomal-mitochondrial crosstalk. | Sci Rep | 2025 | https://conductscience.org/library/papers/41034280 | PubMed |
| 40830872 | Innovative approaches to combat antibiotic resistance: integrating CRISPR/Cas9 and nanoparticles against biofilm-driven infections. | BMC Med | 2025 | https://conductscience.org/library/papers/40830872 | PubMed |
| 40801580 | CRISPR/Cas-Based Ex Vivo Gene Therapy and Lysosomal Storage Disorders: A Perspective Beyond Cas9. | Cells | 2025 | https://conductscience.org/library/papers/40801580 | PubMed |
| 40710901 | Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease. | Neurol Int | 2025 | https://conductscience.org/library/papers/40710901 | PubMed |
| 40677837 | In vivo direct lentiviral gene therapy improves disease pathology in a mucopolysaccharidosis IVA murine model. | Mol Ther Methods Clin Dev | 2025 | https://conductscience.org/library/papers/40677837 | PubMed |
| 40430919 | Evaluation of the PP6D5 Polymer as a Novel Non-Viral Vector in the Development of a CRISPR/nCas9-Based Gene Therapy for Tay-Sachs Disease. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40430919 | PubMed |
| 40362571 | CRISPR/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40362571 | PubMed |
| 39446675 | Lentiviral Vector-Mediated Ex Vivo Hematopoietic Stem Cell Gene Therapy for Mucopolysaccharidosis IVA Murine Model. | Hum Gene Ther | 2024 | https://conductscience.org/library/papers/39446675 | PubMed |
| 39044769 | CRISPR/Cas9 technology in the modeling of and treatment of mucopolysaccharidosis. | Biochem Biophys Rep | 2024 | https://conductscience.org/library/papers/39044769 | PubMed |
| 38368436 | Evidence of epigenetic landscape shifts in mucopolysaccharidosis IIIB and IVA. | Sci Rep | 2024 | https://conductscience.org/library/papers/38368436 | PubMed |
| 38107675 | Iron oxide-coupled CRISPR-nCas9-based genome editing assessment in mucopolysaccharidosis IVA mice. | Mol Ther Methods Clin Dev | 2023 | https://conductscience.org/library/papers/38107675 | PubMed |
| 38003337 | Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38003337 | PubMed |
| 37762535 | Evolution of CRISPR/Cas Systems for Precise Genome Editing. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37762535 | PubMed |
| 36525790 | The landscape of CRISPR/Cas9 for inborn errors of metabolism. | Mol Genet Metab | 2023 | https://conductscience.org/library/papers/36525790 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AAVS1 | 17 | PubTator's text mining | https://conductscience.org/library/genes/17 | NCBI Gene |
| ANXA5 | 308 | PubTator's text mining | https://conductscience.org/library/genes/308 | NCBI Gene |
| GALNS | 2588 | PubTator's text mining | https://conductscience.org/library/genes/2588 | NCBI Gene |
| GLB1 | 2720 | PubTator's text mining | https://conductscience.org/library/genes/2720 | NCBI Gene |
| IKZF3 | 22806 | PubTator's text mining | https://conductscience.org/library/genes/22806 | NCBI Gene |
| SUMF1 | 285362 | PubTator's text mining | https://conductscience.org/library/genes/285362 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36057729
GET https://conductscience.org/api/papers/v1/36057729/references?page=2